Percutaneous Hepatic Perfusion Combined with Ipilimumab and Nivolumab for Metastatic Uveal Melanoma (CHOPIN): A Single-Centre, Open-Label, Randomised Phase 2 Trial
An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study
Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan
New Perspectives in Unresectable Cholangiocarcinoma? Evaluation of Chemosaturation with Percutaneous Hepatic Perfusion as a Palliative Treatment Option
Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis
Phase 1b/2 Trial of Melphalan-Percutaneous Hepatic Perfusion (PHP) Therapy and Nivolumab/Relatlimab in Patients with Metastatic Melanoma and Liver Metastasis
Phase 2 Sequential Treatment of Percutaneous Hepatic Perfusion with Melphalan/Hepatic Delivery System Followed by Tebentafusp in the Treatment of Metastatic Uveal Melanoma
